Industry Briefs: September 10, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: September 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Boehringer Ingelheim has implemented a a flexible set-up and operational approach for disposable technologies within its biopharmaceutical development and manufacturing network. Read More

CSL Biotherapies has been awarded a contract by the US Department of Health and Human Services to supply prepandemic and pandemic vaccine antigens and related services to the US national stockpile. Read More

ICON has expanded its US and United Kingdom bioanalytical facilities to supply biomarker and cell-based assay services. Read More

MedImmune and WuXi AppTec have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China. Read More

Patheon has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions, a priovider of clinical-trial and contract services for secondary packaging. Read More

FDA has approved Pfizer’s Bosulif (bosutinib), new molecular entity for treating chronic myelogenous leukemia. Read More

Sigma-Aldrich and AB SCIEX, a manufacturer of mass spectrometry instruments, have agreed to globally distribute AB SCIEX’s mass spectrometry-based tagging chemistries, called SCIEX iChemistry Solutions, for applications in basic research and applied markets. Read More

People Notes

Aceto has announced that Albert Eilender will step down from his position as CEO, effective Jan. 2, 2013. He will remain as chairman of the board of directors. Salvatore Guccione has been elected to succeed Eilender as CEO, also effective Jan. 2, 2013. Read More

AMRI has appointed Daniel Conlon as senior director of business development. Read More

SciClone Pharmaceuticals has announced announced that Mark Lotter will resign from the position of CEO of the company’s China operations division at the end of 2012. A replacement candidate has not been announced. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here